Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Urol. 2014 Jun;191(6):1721-7. doi: 10.1016/j.juro.2013.12.015. Epub 2013 Dec 14.

Alvimopan, a peripherally acting μ-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 randomized, controlled trial.

Author information

  • 1Cubist Pharmaceuticals, Lexington, Massachusetts.
  • 2University of Texas Health Science Center at San Antonio, San Antonio, Texas.
  • 3Baylor University, Baylor College of Medicine, Houston, Texas.
  • 4Bend Memorial Clinic, Bend, Oregon.
  • 5Vanderbilt University Medical Center, Nashville, Tennessee.
  • 6Cleveland Clinic Foundation, Cleveland, Ohio.
  • 7Mayo Clinic, Rochester, Minnesota.
  • 8Indiana University Medical Center, Indianapolis, Indiana.
  • 9University of Michigan, Ann Arbor, Michigan.
  • 10H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • 11University of Oklahoma College of Medicine, Oklahoma City, Oklahoma.
  • 12University of Chicago Medical Center, Chicago, Illinois.
  • 13University of Colorado Health Science Center, Aurora, Colorado.
  • 14Optum, Eden Prairie, Minnesota.
  • 15University of Texas M.D. Anderson Cancer Center, Houston, Texas. Electronic address: akamat@mdanderson.org.

Abstract

PURPOSE:

We evaluated the effect of alvimopan treatment vs placebo on health care utilization and costs related to gastrointestinal recovery in patients treated with radical cystectomy in a randomized, phase 4 clinical trial.

MATERIALS AND METHODS:

Resource utilization data were prospectively collected and evaluated by cost consequence analysis. Hospital costs were estimated from 2012 Medicare reimbursement rates and medication wholesale acquisition costs. Differences in base case mean costs between the study cohorts for total postoperative ileus related costs (hospital days, study drug, nasogastric tubes, postoperative ileus related concomitant medication and postoperative ileus related readmissions) and total combined costs (postoperative ileus related, laboratory, electrocardiograms, nonpostoperative ileus related concomitant medication and nonpostoperative ileus related readmission) were evaluated by probabilistic sensitivity analysis using a bootstrap approach.

RESULTS:

Mean hospital stay was 2.63 days shorter for alvimopan than placebo (mean±SD 8.44±3.05 vs 11.07±8.23 days, p=0.005). Use of medications or interventions likely intended to diagnose or manage postoperative ileus was lower for alvimopan than for placebo, eg total parenteral nutrition 10% vs 25% (p=0.001). Postoperative ileus related health care costs were $2,340 lower for alvimopan and mean total combined costs were decreased by $2,640 per patient for alvimopan vs placebo. Analysis using a 10,000-iteration bootstrap approach showed that the mean difference in postoperative ileus related costs (p=0.04) but not total combined costs (p=0.068) was significantly lower for alvimopan than for placebo.

CONCLUSIONS:

In patients treated with radical cystectomy alvimopan decreased hospitalization cost by reducing the health care services associated with postoperative ileus and decreasing the hospital stay.

Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

KEYWORDS:

cost-benefit analysis; gastrointestinal tract; ileus; postoperative complications; urinary bladder

PMID:
24342144
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk